Mycosyst 150mg (Fluconazole): Uses, Benefits & Fungal Infection Treatment

Mycosyst 150 mg contains fluconazole, a triazole antifungal. It is a single-dose oral therapy for uncomplicated vulvovaginal candidiasis (yeast infection).

Indications

• Vulvovaginal candidiasis (acute & recurrent): 150 mg single dose; repeat in 3 days if needed for recurrent.
• Oropharyngeal / esophageal candidiasis: 200 mg day 1, then 100 mg daily × 7–14 days (esophageal: 14–21 days).
• Systemic Candida infections: Candidemia, disseminated candidiasis — 400–800 mg daily (IV/PO).
• Cryptococcal meningitis: 400 mg day 1, then 200–400 mg daily × 10–12 weeks (after amphotericin induction).
• Prophylaxis: In immunocompromised (transplant, chemo, advanced HIV) — 150–400 mg weekly or daily.
• Dermatophytoses (tinea corporis, cruris, pedis): 150 mg weekly × 2–4 weeks (off-label in some regions; terbinafine/itraconazole preferred).

Key Advantages

• Excellent oral bioavailability (>90%) — no food effect.
• Penetrates CSF, saliva, skin, nails, vaginal mucosa.
• Long half-life (~30 hrs) → once-daily/weekly dosing.
• Fewer drug interactions than itraconazole/ketoconazole (still: CYP2C9/3A4 substrate/inhibitor).

Safety Notes

• QT prolongation risk (avoid with other QT drugs).
• Hepatotoxicity (monitor LFTs in prolonged courses).
• Pregnancy: Category D (high-dose chronic); single 150 mg generally avoided unless benefit > risk.
• Renal adjustment: CrCl <50 mL/min → 50% dose reduction.